The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials

Abstract

This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to summarize the effect of resveratrol intake on weight loss. We searched the following databases until July 2018: MEDLINE, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials. Data were pooled using the inverse variance method and expressed as standardized mean difference (SMD) with 95% confidence intervals (95% CI). Out of 831 reports, 36 RCTs were eligible for including to our meta-analysis. The pooled results, using random-effects model showed that resveratrol supplementation significantly decreased body weight (SMD?=??0.17; 95% CI, ?0.33, ?0.01; P?=?0.03; I²: 62.6), body mass index (BMI) (SMD?=??0.20; 95% CI, ?0.35, ?0.05; P?=?0.01; I²: 60.6), fat mass (SMD?=??0.32; 95% CI, ?0.62, ?0.03; P?=?0.03; I²: 77.9) and waist circumference (WC) (SMD?=??0.42; 95% CI, ?0.68, ?0.16; P?=?0.001; I²: 75.2), and significantly increased lean mass (SMD?=?1.21; 95% CI, 0.75, 1.67; P?<?0.001; I²: 87.6). We found no significant effect of resveratrol administration on leptin (SMD?=??0.20; 95% CI, ?0.68, 0.27; P?=?0.40; I²: 85.3) and adiponectin levels (SMD?=?0.08; 95% CI, ?0.39, 0.55; P?=?0.74; I²: 91.0). Resveratrol supplementation significantly decreased body weight in obese patients (SMD ?0.43; 95% CI, ?0.60, ?0.26) compared with other diseases (SMD 0.02; 95% CI, ?0.29, 0.33), and type 2 diabetes mellitus (SMD ?0.17; 95% CI, ?0.37, 0.02). Overall, the current meta-analysis demonstrated that resveratrol intake significantly reduced weight, BMI, WC and fat mass, and significantly increased lean mass, but did not affect leptin and adiponectin levels.     

The effects of caffeine intake on weight loss: a systematic review and dos-response meta-analysis of randomized controlled trials

Abstract

This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effect of caffeine intake on weight loss. We searched the following databases until November 2017: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The relevant data were extracted and assessed for quality of the studies according to the Cochrane risk of bias tool. We estimated an intake-status regression coefficient (Beta) for each primary study and estimated the overall pooled Beta and SE using random effects meta-analysis on a double-log scale. Heterogeneity between studies was assessed by the Cochran Q statistic and I-squared tests (I²). Thirteen RCTs with 606 participants were included in the meta-analyses. The overall pooled Beta for the effect of caffeine intake was 0.29 (95%CI: 0.19, 0.40; Q = 124.5, I²?=?91.2%) for weigh, 0.23 (95%CI: 0.09, 0.36; Q = 71.0, I²?=?93.0%) for BMI, and 0.36 (95% CI: 0.24, 0.48; Q = 167.36, I²?=?94.0%) for fat mass. For every doubling in caffeine intake, the mean reduction in weight, BMI, and fat mass increased 2 Beta-fold (20.29 = 1.22, 20.23 = 1.17, and 20.36 = 1.28), which corresponding to 22, 17, and 28 percent, respectively. Overall, the current meta-analysis demonstrated that caffeine intake might promote weight, BMI and body fat reduction.     

The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials

Abstract

Aims: This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to determine the effect of quercetin administration on lipid profiles and inflammatory markers among patients with metabolic syndrome (MetS) and related disorders.

Methods: We searched systematically online databases including Cochrane Library, EMBASE, MEDLINE, and Web of Science to identify the relevant RCTs until November 2018. Q-test and I² statistics were applied to assess heterogeneity among included studies. Data were combined using fixed- or random-effects model and presented as standardized mean difference (SMD) with 95% confidence interval (CI).

Results: Out of 591 citations, 16 RCTs were included in the meta-analysis. The pooled findings showed that quercetin consumption significantly decreased total-cholesterol (SMD = ?0.98; 95% CI, ?1.48, ?0.49; p?<?0.001; I²: 94.0), LDL-cholesterol (SMD = ?0.88; 95% CI, ?1.35, ?0.41; p?<?0.001; I²: 92.7) and C-reactive protein (CRP) levels (?0.64; 95% CI, ?1.03, ?0.25; p?=?0.001; I²: 90.2). While, quercetin supplementation did not significantly affect triglycerides (TG) (SMD = ?0.32; 95% CI, ?0.68, 0.04; p?=?0.08; I²: 84.8), HDL-cholesterol (SMD = 0.20; 95% CI, ?0.20, 0.24; p?=?0.84; I²: 70.6), interleukin 6 (IL-6) (SMD = ?0.69; 95% CI, ?1.69, 0.31; p?=?0.17; I²: 94.5) and tumor necrosis factor-alpha (TNF-α) levels (SMD = ?0.06; 95% CI, ?0.25, 0.14; p?=?0.58; I²: 35.6)

Conclusions: In summary, the current meta-analysis demonstrated that quercetin supplementation significantly reduced total-cholesterol, LDL-cholesterol, and CRP levels, yet did not affect triglycerides, HDL-cholesterol, IL-6 and TNF-α among patients with MetS and related disorders.     

The effects of psyllium supplementation on body weight,body mass index and waist circumference in adults: A systematic review and dose-response meta-analysis of randomized controlled trials

Abstract

Background: Previous studies reported inconsistent findings regarding the effects of psyllium supplementation on obesity measures. This systematic review and meta-analysis was performed to summarize data from available randomized clinical trials (RCTs) on the effect of psyllium supplementation on body weight, body mass index (BMI), and waist circumference (WC) in adults.

Methods: PubMed, SCOPUS, Cochrane Library, and Google Scholar were searched to identify relevant articles up to August 2018. The effect sizes were presented as weighted mean difference (WMD) and 95% confidence intervals (CI) by using random effects model. To detect dose-response relationships, we used fractional polynomial modeling.

Results: A total of 22 RCTs were included. Meta-analysis did not find any significant effect of psyllium supplementation on body weight (MD: ?0.28?kg, 95% CI: ?0.78, 0.21, p?=?0.268), BMI (MD: ?0.19?kg/m², 95% CI: ?0.55, 0.15, p?=?0.27) and WC (MD: ?1.2?cm, 95% CI: ?2.6, 0.2, p?=?0.09). Subgroup analysis showed that psyllium dosage, kind of psyllium administration, duration of trial, study design, sample size, and gender were potential sources of heterogeneity. Moreover, there was nonlinear association between duration of psyllium consumption, BMI and WC.

Conclusion: Psyllium supplementation does not reduce body weight, BMI, and WC significantly.     

The effects of chitosan supplementation on body weight and body composition: a systematic review and meta-analysis of randomized controlled trials

Abstract

Although several clinical trials studied the efficacy of chitosan on weight loss, controversial results have been found. Herein, we evaluated randomized controlled trials (RCTs) of chitosan consumption in adult participants on body weight and body composition through a meta-analysis with trial sequential analysis (TSA). We searched EMBASE, MEDLINE, Web of Science, and CENTRAL databases. The primary body composition indices including body weight, body mass index (BMI), waist circumference, body fat, and hip circumference were extracted. The quality of included articles was assessed according to the Cochrane risk of bias tool. Data were pooled using the random-effects models and calculated as weighted mean difference (WMD) with 95% confidence intervals (CI). Heterogeneity investigated using I² statistics. TSA, subgroup analyses, sensitivity analysis, meta-regression and publication bias were also evaluated. Overall, 15 eligible trials (18 treatment arms) with 1130 subjects were included. The pooled analyses revealed a significant reduction in body weight (WMD, ?0.89?kg; 95% CI, ?1.41 to ?0.38; P?=?0.0006), BMI (WMD, ?0.39?kg/m²; 95% CI, ?0.64 to ?0.14; P?=?0.002) and body fat (WMD, ?0.69%; 95% CI, ?1.02 to ?0.35; P?=?0.0001) receiving chitosan supplementation. Subgroup analyses also showed that consuming chitosan in dose (>2.4?g/d), shorter-term (<12?weeks), studies with parallel design and studies including participants with obese or overweight had positive effects on body composition. TSA provided conclusive evidence for the benefit of chitosan supplementation. Our findings provided evidence that chitosan consumption might be a useful adjunctive pharmacological therapeutic tool for body weight management particularly in overweight/obese participants. Further well-constructed clinical trials that target body weight and body composition as their primary outcomes are needed.     

The effect of grapefruits (Citrus paradisi) on body weight and cardiovascular risk factors: A systematic review and meta-analysis of randomized clinical trials

The aim of this systematic review was to evaluate the evidence for or against the effectiveness of grapefruits (Citrus paradisi) on body weight, blood pressure, and lipid profile. Electronic searches were conducted in MEDLINE, EMBASE, AMED, and the Cochrane Clinical Trials databases to identify relevant human randomized clinical trials (RCTs). Hand searches of bibliographies were also conducted. Only overweight and obese subjects were included. The reporting quality was assessed using the CONSORT checklist, and the strength of the overall body of evidence was rated based on the GRADE criteria. One hundred and fifty four citations were identified and three RCTs with a total of 250 participants were included. The RCTs were of moderate quality. A meta-analysis for change in body weight failed to reveal a significant difference between grapefruits and controls, MD: ?0.45 kg (95% CI: ?1.06 to 0.16; I² = 53%, but analysis revealed a significant decrease in systolic blood pressure, MD: ?2.43 mmHg (95% CI: ?4.77 to ?0.09; I² = 0%). Paucity in the number of RCTs, short durations of interventions, and lack of an established minimum effective dose limit the conclusions that can be drawn about the effects of grapefruit on body weight and metabolic parameters. Further clinical trials evaluating the effects of grapefruit are warranted.     

Prevalence of overweight and obesity among indigenous populations in Canada: A systematic review and meta-analysis

Previous studies on overweight and obesity among indigenous peoples in Canada have been inconclusive. A systematic review was conducted on the prevalence of overweight and obesity among Canadian indigenous populations. Major bibliographic databases were searched for relevant studies published between January 1990 and June 2013. We reviewed 594 abstracts and included 41 studies in the meta-analyses. Using the heterogeneity test (Cochrane Q) results, the overall prevalence was estimated using fixed- or random-effects model. Nonadults (<18 years) had a pooled prevalence of overweight and obesity at 29.8% (95% CI: 25.2–34.4) and 26.5% (95% CI: 21.8–31.3), respectively. The pooled prevalence of overweight and obesity among adults were 29.7% (95% CI: 28.2–31.2) and 36.6% (95% CI: 32.9–40.2), respectively. Adult males had higher overweight prevalence than females (34.6% vs. 26.6%), but lower obesity prevalence (31.6% vs. 40.6%). Nonadult girls had higher prevalence than boys [overweight: 27.6%; 95% CI: 22.6–32.7 vs. 24.7%; 95% CI: 19.0–30.5; obesity: 28.6%; 95% CI: 20.3–36.9 vs. 25.1%; 95% CI: 13.8–36.4]. Nonadult Inuit had the highest overweight and lowest obesity prevalence. Although Inuit adult had the lowest prevalence of overweight (28.7%; 95% CI: 27.3–30.2) and obesity (32.3%; 95% CI: 25.5–39.1), it was relatively high. This study highlights the need for nutritional intervention programs for obesity prevention among indigenous populations in Canada.     

Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized,controlled, clinical trials

Introduction: Results of previous clinical trials evaluating the effect of resveratrol supplementation on blood pressure (BP) are controversial.

Purpose: We aimed to assess the impact of resveratrol on BP through systematic review of literature and meta-analysis of available randomized, controlled clinical trials (RCTs).

Methods: Literature search included SCOPUS, PubMed-Medline, ISI Web of Science and Google Scholar databases up to 17th October 2017 to identify RCTs investigating the impact of resveratrol on BP. Two review authors independently extracted data on study characteristics, methods and outcomes. Overall, the impact of resveratrol on BP was reported in 17 trials.

Results: Administration of resveratrol did not significantly affect neither systolic BP [weighted mean difference (WMD): ?2.5 95% CI:(-5.5, 0.6) mmHg; p=0.116; I²=62.1%], nor diastolic BP [WMD: ?0.5 95% CI:(-2.2, 1.3) mmHg; p=0.613; I²=50.8], nor mean BP [MAP; WMD: ?1.3 95% CI:(-2.8, 0.1) mmHg; p=0.070; I²=39.5%] nor pulse pressure [PP; WMD: ?0.9 95% CI:(-3.1, 1.4) mmHg; p=0.449; I²=19.2%]. However, significant WMDs were detected in subsets of studies categorized according to high resveratrol daily dosage (≥300 mg/day) and presence of diabetes. Meta-regression analysis revealed a positive association between systolic BP-lowering resveratrol activity (slope: 1.99; 95% CI: 0.05, 3.93; two-tailed p= 0.04) and Body Mass Index (BMI) at baseline, while no association was detected neither between baseline BMI and MAP-lowering resveratrol activity (slope: 1.35; 95% CI: ?0.22, 2.91; two-tailed p= 0.09) nor between baseline BMI and PP-lowering resveratrol activity (slope: 1.03; 95% CI: ?1.33, 3.39; two-tailed p= 0.39). Resveratrol was fairly well-tolerated and no serious adverse events occurred among most of the eligible trials.

Conclusion: The favourable effect of resveratrol emerging from the current meta-analysis suggests the possible use of this nutraceutical as active compound in order to promote cardiovascular health, mostly when used in high daily dose (≥300 mg/day) and in diabetic patients.     

Effect of wheat germ on metabolic markers: a systematic review and meta-analysis of randomized controlled trials

Food Science and Biotechnology - This systematic review and meta-analysis aim to evaluate the association of wheat germ interventions and metabolic markers. An electronic search was performed by...     

Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials

Objective: The aim of this systematic review and meta-analysis was to determine and clarify the impact of curcuminoids on serum lipid levels. Methods: Randomized controlled trials (RCTs) investigating the effects of curcuminoids on plasma lipids were searched in PubMed-Medline, Scopus, Web of Science databases (from inception to April 3^rd, 2017). A random-effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate the impact of potential confounders on lipid concentrations. Results: A meta-analysis of 20 RCTs with 1427 participants suggested a significant decrease in plasma concentrations of triglycerides (WMD: ?21.36 mg/dL, 95% CI: ?32.18, ?10.53, p < 0.001), and an elevation in plasma HDL-C levels (WMD: 1.42 mg/dL, 95% CI: 0.03, 2.81, p = 0.046), while plasma levels of LDL-C (WMD: ?5.82 mg/dL, 95% CI: ?15.80, 4.16, p = 0.253) and total cholesterol (WMD: ?9.57 mg/dL, 95% CI: ?20.89, 1.75, p = 0.098) were not altered. The effects of curcuminoids on lipids were not found to be dependent on the duration of supplementation. Conclusion: This meta-analysis has shown that curcuminoid therapy significantly reduces plasma triglycerides and increases HDL-C levels.     

Correction to: Effect of wheat germ on metabolic markers: a systematic review and meta-analysis of randomized controlled trials

Food Science and Biotechnology - The article “Effect of wheat germ on metabolic markers: a systematic review and meta-analysis of randomized controlled trials”, written by Humna Liaqat,...     

Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials

Background: In spite of promising experimental findings, randomized controlled trials (RCTs) have yielded mixed results on the impact of quercetin supplementation on plasma lipid levels.

Aim: The present study aimed to quantify the effects of quercetin on plasma lipids using a meta-analysis of RCTs.

Methods: A systematic literature search of Medline was conducted for RCTs that investigated the efficacy of quercetin supplementation on plasma lipids comprising total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid concentrations using a random-effects model. Meta-regression analysis was conducted to assess the effect of quercetin dose and duration of supplementation as moderators on the calculated effect measures.

Results: Five RCTs totaling 442 subjects (221 in the quercetin and 221 in the control group) fulfilled the eligibility criteria and selected for analyses. Combined estimate of effect size for the impact of quercetin on plasma LDL-C (WMD: 1.43 mg/dL, 95% CI: ?0.92–3.78, p = 0.23), HDL-C (WMD: 0.26 mg/dL, 95% CI: ?0.74–1.25, p = 0.61) and triglycerides (WMD: ?9.42 mg/dL, 95% CI: ?27.80–8.96, p = 0.32) was not statistically significant. However, a borderline significant but clinically non-relevant increase in total cholesterol was observed (WMD: 3.13 mg/dL, 95% CI: ?0.01–6.27, p = 0.05). When the analysis was confined to the subgroups of studies with quercetin doses ≥500 mg/day and follow-up of ≥ 4 weeks, a significant increase in total cholesterol (WMD: 3.57 mg/dL, 95% CI: 0.21–6.92, p = 0.04) and a decline in triglycerides (WMD: ?24.54 mg/dL, 95% CI: ?33.09 to ?15.99, p < 0.00001) was observed, but LDL-C and HDL-C concentrations remained unchanged (p > 0.05). Changes in plasma triglycerides, but not other indices of lipid profile, were significantly associated with quercetin dose (slope: ?0.057; 95% CI: ?0.103 to ?0.010; p = 0.02) and duration of supplementation (slope: ?5.314; 95% CI: ?9.482 to ?1.147; p = 0.01).

Conclusion: Available evidence from RCTs does not suggest any clinically relevant effect of quercetin supplementation on plasma lipids, apart from a significant reduction of triglycerides at doses above 50 mg/day.     

The effects of supplementation with conjugated linoleic acid on anthropometric indices and body composition in overweight and obese subjects: A systematic review and meta-analysis

Abstract

Clinical trials have indicated conflicting results on the effects of conjugated linoleic acid (CLA) on obesity. The present study aimed to systematically review controlled clinical trials examining the effects of CLA on anthropometric indices and body composition in overweight and obese subjects. Pubmed, Scopus, Web of science, and Cochrane databases were searched between 2000 and December 2017 with no language restriction. Placebo-controlled clinical trials that reported anthropometric indices and body composition in overweight and obese subjects were included. Random-effect model was used to pool the effect estimates. Of 4032 publications, 13 trials were included for the meta-analysis. Pooled effect sizes indicated that CLA significantly reduced body weight (WMD: ?0.52 kg, 95% CI: ?0.83, ?0.21; I²: 48.0%, p?=?0.01), BMI (WMD: ?0.23 kg/m², 95% CI: ?0.39,???0.06; I²: 64.7%, p?=?0.0001), FM (WMD: ?0.61 kg, 95% CI: ?0.98, ?0.24; I²: 53.8%, p?=?0.01) and increased LBM (WMD: 0.19 kg, 95% CI: 0.04, 0.34; I²: 81.4%, p?=?0.0001) compared to the placebo group. However, the effects of CLA on WC (WMD: 0.05 cm, 95% CI: ?0.01, 0.1; I²: 0%, p?=?0.93) was not significant. Additionally, its impact on body weight in subjects older than 44 year (WMD: ?1.05 kg, 95% CI: ?1.75, ?0.35; I²: 57.0%, p?=?0.01), with longer duration (more than 12 weeks) (WMD: ?1.29 kg, 95% CI: ?2.29, ?0.29; I²: 70.3%, p?=?0.003) and dosage more than 3.4 g/day (WMD: ?0.77 kg, 95% CI: ?1.28, ?0.25; I²: 62.7%, p?=?0.004) were greater than comparative groups. Supplementation with CLA can slightly reduce body weight and FM and increase LBM in overweight and obese subjects. However, its efficacy was not clinically considerable. Further studies with high methodological quality are needed to shed light on the effects of CLA on anthropometric indices in overweight and obese subjects.     

Metabolic effects of aspartame in adulthood: A systematic review and meta-analysis of randomized clinical trials

Data about harms or benefits associated with the consumption of aspartame, a nonnutritive sweetener worldwide consumed, are still controversial. This systematic review and meta-analysis of randomized controlled clinical trials aimed to assess the effect of aspartame consumption on metabolic parameters related to diabetes and obesity. The search was performed on Cochrane, LILACS, PubMed, SCOPUS, Web of Science databases, and on a gray literature using Open Grey, Google Scholar, and ProQuest Dissertations &; Theses Global. Searches across all databases were conducted from the earliest available date up to April 13, 2016, without date and language restrictions. Pooled mean differences were calculated using a random or fixed-effects model for heterogeneous and homogenous studies, respectively. Twenty-nine articles were included in qualitative synthesis and twelve, presenting numeric results, were used in meta-analysis. Fasting blood glucose (mmol/L), insulin levels (μU/mL), total cholesterol (mmol/L), triglycerides concentrations (mmol/L), high-density lipoprotein cholesterol (mmol/L), body weight (kg), and energy intake (MJ) were considered as the main outcomes in subjects that consumed aspartame, and results were presented as mean difference; % confidence interval, range. Aspartame consumption was not associated with alterations on blood glucose levels compared to control (?0.03 mmol/L; 95% CI, ?0.21 to 0.14) or to sucrose (0.31 mmol/L; 95% CI, ?0.05 to 0.67) and on insulin levels compared to control (0.13 μU/mL; 95% CI, ?0.69 to 0.95) or to sucrose (2.54 μU/mL; 95% CI, ?6.29 to 11.37). Total cholesterol was not affected by aspartame consumption compared to control (?0.02 mmol/L; 95% CI, ?0.31 to 0.27) or to sucrose (?0.24 mmol/L; 95% CI, ?0.89 to 0.42). Triglycerides concentrations were not affected by aspartame consumption compared to control (0.00 mmol/L; 95% CI, ?0.04 to 0.05) or to sucrose (0.00 mmol/L; 95% CI, ?0.09 to 0.09). High-density lipoprotein cholesterol serum levels were higher on aspartame compared to control (?0.03 mmol/L; 95% CI, ?0.06 to ?0.01) and lower on aspartame compared to sucrose (0.05 mmol/L; 95% CI, 0.02 to 0.09). Body weight did not change after aspartame consumption compared to control (5.00 kg; 95% CI, ?1.56 to 11.56) or to sucrose (3.78 kg; 95% CI, ?2.18 to 9.74). Energy intake was not altered by aspartame consumption compared to control (?0.49 MJ; 95% CI, ?1.21 to 0.22) or to sucrose (?0.17 MJ; 95% CI, ?2.03 to 1.69). Data concerning effects of aspartame on main metabolic variables associated to diabetes and obesity do not support a beneficial related to its consumption.     

Sodium status and the metabolic syndrome: A systematic review and meta-analysis of observational studies

The prevalence of metabolic syndrome (MetS) has been greatly increased, worldwide. In recent years, investigators have proposed that sodium might contribute to the development of metabolic syndrome; however, the published data were conflicting. The present systematic review aimed to summarize the evidence from observational studies in this regard. We conducted a systematic search for relevant observational studies investigating the association between sodium status and MetS, published until June 2017 in electronic databases including PubMed, EMBASE, Scopus and Google Scholar. Summary effects were derived using random effects model. After screening the records, seventeen publications with 66,274 participants were eligible to be included in the systematic review and meta-analysis. The analysis revealed that subjects with MetS have significantly higher levels of sodium compared to healthy controls (Hedges' g = 0.21, 95% CI: 0.12, 0.29, I² = 68.6). Subgroup analyses revealed that the difference was significant when the sodium status was assessed using urinary sodium levels. The random effects meta-regression analysis also revealed that body sodium level increases with the number of MetS components. Furthermore, participants with highest dietary/urinary or serum sodium levels had 37% higher chance of developing MetS when compared with participants with the lowest sodium levels (OR = 1.37 95%CI: 1.31, 1.42, I² = 86.9). The current meta-analysis revealed that higher sodium input into the body is directly associated with the likelihood of MetS. Prospective cohort studies and well-designed randomized clinical trials considering the effect of sodium restricted diets on the risk of MetS as an outcome are necessary to represent the causal association.     

Effect of egg consumption on inflammatory markers: a systematic review and meta-analysis of randomized controlled clinical trials

There is little evidence about whether eggs affect inflammation. The aim of this meta-analysis was to explore the effects of egg consumption on inflammation. A systematic search of online databases (Institute for Scientific Information (ISI), Scopus, Ovid, PubMed, Cochrane) was used to gather clinical trials that assessed the effect of egg consumption on circulating inflammatory biomarkers. Using a random-effects model, pooled weighted mean differences (WMD) and corresponding standard deviations (SD) were calculated. Of the 21 eligible studies found, nine trials were eligible for analysis. Eight trials assessed high-sensitivity C-reactive protein (hs-CRP), four trials assessed interleukin-6 (IL-6), and five trials assessed tumor necrosis factor-alpha (TNF-α). Egg consumption did not affect hs-CRP (WMD 0.24 mg/L; 95% CI: -0.43, 0.90; I² = 53.8; P = 0.48), IL-6 (WMD 0.20 pg/mL; 95% CI: -0.71, 1.11; I² = 69.3; P = 0.50), and TNF-α (WMD: -0.38 pg/mL; 95% CI: -0.87, 0.10; I² = 0.00; P = 0.12) relative to controls. Overall, this meta-analysis revealed that egg consumption had no significant effect on serum biomarkers of inflammation in adults. © 2019 Society of Chemical Industry